Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates, and other forward-looking statements,
including without limitation statements regarding: our expectations regarding 2022 newsflow items; expectations regarding Opzelura; the potential opportunities offered by
Incyte’s multiple dermatology programs and expectations regarding the timing of clinical trials for same; the potential for improvement in treatment of patients with MF and
opportunities offered by the LIMBER program; the potential for targeted combinations and new molecules for MPNs and GVHD; the opportunities for continued growth in
treatments for MPNs/GVHD and expectations regarding the timing of clinical trials and regulatory submissions for same; the opportunities for growth offered by tafasitamab;
expectations for other assets in development, including parsaclisib in warm autoimmune hemolytic anemia and programs in oral PD-L1, adenosine, and LAG-3; the
transformational growth potential of Incyte’s portfolio, including expectations regarding continued growth from Jakafi and the opportunities presented by once-a-day
ruxolitinib and by axatilimab in GVHD, expectations regarding the commercialization of Monjuvi/Minjuvi and Pemazyre, as well as potential future commercial opportunities
presented by parsaclisib and Incyte’s oral PD-L1 and adenosine programs, expectations for Opzelura in atopic dermatitis and vitiligo, ruxolitimab cream in other indications,
and INCB54707, and the potential for growth in royalties from new indications and new geographies
相关推荐
热门下载
推荐
快速链接
热门标签
关注我们
扫码关注我们
了解更多相关信息